Patents by Inventor Gary R. Pasternack
Gary R. Pasternack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040208853Abstract: Methods and devices for sanitation using bacteriophage are disclosed. According to one embodiment of the present invention, a method for sanitation using at least one bacteriophage includes the steps of (1) storing the at least one bacteriophage in a container; and (2) applying the at least one bacteriophage to a surface to be sanitized with a dispersing mechanism. According to another embodiment of the present invention, a sanitation device that dispenses at least one bacteriophage includes a container, at least one bacteriophage stored in the container, and a dispersing mechanism that disperses the at least one bacteriophage from the container.Type: ApplicationFiled: December 11, 2003Publication date: October 21, 2004Applicant: Intralytix, Inc.Inventors: Alexander Sulakvelidze, J. Glenn Morris, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20040191224Abstract: Methods and devices for sanitation using bacteriophage are disclosed. According to one embodiment of the present invention, a method for sanitation using at least one bacteriophage includes the steps of (1) storing the at least one bacteriophage in a container; and (2) applying the at least one bacteriophage to a surface to be sanitized with a dispersing mechanism. According to another embodiment of the present invention, a sanitation device that dispenses at least one bacteriophage includes a container, at least one bacteriophage stored in the container, and a dispersing mechanism that disperses the at least one bacteriophage from the container.Type: ApplicationFiled: December 11, 2003Publication date: September 30, 2004Applicant: Intralytix, Inc.Inventors: Alexander Sulakvelidze, J. Glenn Morris, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20040186176Abstract: This invention provides methods for treating a mycobacterial infection by administering to an animal a pharmaceutical composition containing a compound having the formula R—SOn-Z-CO—Y, where R is an alkyl group having 6-20 carbons; Z is a radical selected from —CH2—, —O—, and —NH—, two of these radicals coupled together, or —CH2═CH2—; Y is —NH2, O—CH2—C6H5, —CO—CO—O—CH3, or O—CH3; and n is 1 or 2. It has been discovered that these compounds inhibit growth of microbial cells which synthesize &agr;-substitued. &bgr;-hydroxy fatty acids, particularly corynemycolic acid, nocardic acid, and mycolic acid. These compounds may be used to inhibit growth of mycobacterial cells, such as Mycobacterium tuberculosis, drug-resistant M. tuberculosis, M. avium intracellulare, and M. leprae.Type: ApplicationFiled: January 27, 2004Publication date: September 23, 2004Applicant: The Johns Hopkins University of MedicineInventors: Craig A. Townsend, James D. Dick, Gary R. Pasternack, Francis P. Kuhajda, Nicole M. Parrish
-
Patent number: 6713654Abstract: This invention provides methods for treating a mycobacterial infection by administering to an animal a pharmaceutical composition containing a compound having the formula R—SOn—Z—CO—Y, where R is an alkyl group having 6-20 carbons; Z is a radical selected from —CH2—, —O—, and —NH—, two of these radicals coupled together, or —CH2═CH2—; Y is —NH2, O—CH2—C6H5, —CO—CO—O—CH3, or O—CH3; and n is 1 or 2. It has been discovered that these compounds inhibit growth of microbial cells which synthesize &agr;-substitued, &bgr;-hydroxy fatty acids, particularly corynemycolic acid, nocardic acid, and mycolic acid. These compounds may be used to inhibit growth of mycobacterial cells, such as Mycobacterium tuberculosis, drug-resistant M. tuberculosis, M. avium intracellulare, and M. leprae.Type: GrantFiled: August 28, 2000Date of Patent: March 30, 2004Assignee: The Johns Hopkins University School of MedicineInventors: Craig A. Townsend, James D. Dick, Gary R. Pasternack, Francis P. Kuhajda, Nicole M. Parrish
-
Patent number: 6699701Abstract: Methods and devices for sanitation using bacteriophage are disclosed. According to one embodiment of the present invention, a method for sanitation using at least one bacteriophage includes the steps of (1) storing the at least one bacteriophage in a container; and (2) applying the at least one bacteriophage to a surface to be sanitized with a dispersing mechanism. According to another embodiment of the present invention, a sanitation device that dispenses at least one bacteriophage includes a container, at least one bacteriophage stored in the container, and a dispersing mechanism that disperses the at least one bacteriophage from the container.Type: GrantFiled: January 11, 2001Date of Patent: March 2, 2004Assignee: Intralytix, Inc.Inventors: Alexander Sulakvelidze, J. Glenn Morris, Jr., Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20040029250Abstract: Methods and devices for sanitation using bacteriophage are disclosed. According to one embodiment of the present invention, a method for sanitation using at least one bacteriophage includes the steps of (1) storing the at least one bacteriophage in a container; and (2) applying the at least one bacteriophage to a surface to be sanitized with a dispersing mechanism. According to another embodiment of the present invention, a sanitation device that dispenses at least one bacteriophage includes a container, at least one bacteriophage stored in the container, and a dispersing mechanism that disperses the at least one bacteriophage from the container.Type: ApplicationFiled: January 11, 2001Publication date: February 12, 2004Inventors: Alexander Sulakvelidze, J. Glenn Morris, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20030129631Abstract: pp32 is a member of a highly conserved family of differentiation-regulated nuclear proteins that is highly expressed in nearly all human prostatic adenocarcinomas of Gleason Grade ≧5. This contrasts with the low percentage of prostate tumors that express molecular alterations in proto-oncogens or demonstrate tumor suppressor mutation or loss of heterozygosity. By analysis of specimens of human prostatic adenocarcinoma and paired adjacent normal prostate from three individual patients, the inventors have shown that normal prostate continues to express normal pp32, whereas three of three sets of RT-PCR-amplified transcripts from prostatic adenocarcinomas display multiple cancer-associated coding sequence changes. The cancer-associated sequence changes appear to be functionally significant. Normal pp32 exerts antineoplastic effects through suppression of transformation. In contrast, cancer-associated pp32 variants augment, rather than inhibit, transformation.Type: ApplicationFiled: October 18, 2002Publication date: July 10, 2003Inventors: Gary R. Pasternack, Gerald J. Kocheavar, Jonathan R. Brody, Shrihari S. Kadkol
-
Patent number: 6040173Abstract: Three mammalian proteins are disclosed which are useful in the diagnosis and prognosis of tumors of lymphoid and epithelial origin. The three proteins are immunologically related to each other. The level of expression of the proteins correlates with the malignant potential of lymphoid and epithelial tumors. In addition, in some cases the subcellular location of the proteins is indicative of malignant potential. Antibodies reactive with the proteins are disclosed as diagnostic tools, as are nucleic acid probes and primers for quantitating the messenger RNAs encoding the proteins. Methods for preparing and purifying the proteins are also taught.Type: GrantFiled: June 6, 1995Date of Patent: March 21, 2000Assignee: Johns Hopkins UniversityInventor: Gary R. Pasternack
-
Patent number: 5981575Abstract: Weight loss was noted in nude mice treated with cerulenin, a non-competitive inhibitor of FAS. Sustained reduction of adipocyte mass in humans without toxicity would significantly impact disease prevention worldwide. Aside from psychological and self-esteem improvement, weight loss via reduction of adipocyte mass may: (1) ameliorate hyperglycemia associated with non-insulin-dependent diabetes mellitus thereby reducing diabetic complications such as arterial disease, blindness, cataracts, etc., (2) reduce hypertension, (3) reduce risk of coronary artery vascular disease and stroke, and (4) reduce the risk of other complications of massive obesity such as osteoarthritis, surgical complications, etc. There is also potential use in livestock and poultry to reduce the saturated fat content of meat products. Therefore FAS inhibitors are disclosed herein as novel agents for weight reduction. A family of compounds (.gamma.-substituted-.alpha.-methylene-.beta.-carboxy-.gamma.Type: GrantFiled: January 27, 1998Date of Patent: November 9, 1999Assignee: Johns Hopkins University, TheInventors: Francis P. Kuhajda, Gary R. Pasternack, Craig A. Townsend, Neelakandha S. Mani
-
Patent number: 5874234Abstract: Three mammalian are disclosed which are useful in the diagnosis and prognosis of tumors of lymphoid and epithelial origin. The three proteins are immunologically related to each other. The level of expression of the proteins correlates with the malignant potential of lymphoid and epithelial tumors. In addition, in some cases the subcellular location of the proteins is indicative of malignant potential. Antibodies reactive with the proteins are disclosed as diagnostic tools, as are nucleic acid probes and primers for quantitating the messenger RNAs encoding the proteins. Methods for preparing and purifying the proteins are also taught.Type: GrantFiled: June 6, 1995Date of Patent: February 23, 1999Assignee: Johns Hopkins UniversityInventor: Gary R. Pasternack
-
Patent number: 5872217Abstract: A method of determining the prognosis of a solid tumor is provided, in which a sample from a patient bearing a tumor is assayed for the presence of a protein which is immunologically cross-reactive with the hpr gene product, but not with haptoglobin 1 or haptoglobin 2. Also provided is a method for preparing antibodies specific for this diagnostic marker which correlates with early relapse and metastasis of breast and other cancers. The marker can be detected using immunological methods employing antibodies specific for Hpr protein and not cross-reactive with haptoglobins 1 or 2.Type: GrantFiled: June 5, 1995Date of Patent: February 16, 1999Assignee: The Johns Hopkins UniversityInventors: Francis P. Kuhajda, Gary R. Pasternack
-
Patent number: 5864011Abstract: A method of determining the prognosis of a solid tumor is provided, in which a sample from a patient bearing a tumor is assayed for the presence of a protein which is immunologically cross-reactive with the hpr gene product, but not with haptoglobin 1 or haptoglobin 2. Also provided is a method for preparing antibodies specific for this diagnostic marker which correlates with early relapse and metastasis of breast and other cancers. The marker can be detected using immunological methods employing antibodies specific for Hpr protein and not cross-reactive with haptoglobins 1 or 2.Type: GrantFiled: June 5, 1995Date of Patent: January 26, 1999Assignee: The Johns Hopkins UniversityInventors: Francis P. Kuhajda, Gary R. Pasternack
-
Patent number: 5759791Abstract: A method of determining the prognosis of a solid tumor is provided, in which a sample from a patient bearing a tumor is assayed for the presence of a protein which is immunologically cross-reactive with the hr gene product, but not with haptoglobin 1 or haptoglobin 2. Also provided is a method for preparing antibodies specific for this diagnostic marker which correlates with early relapse and metastasis of breast and other cancers. The marker can be detected using immunological methods employing antibodies specific for Hpr protein and not cross-reactive with haptoglobins 1 or 2.Type: GrantFiled: January 24, 1994Date of Patent: June 2, 1998Assignee: The Johns Hopkins UniversityInventors: Francis P. Kuhajda, Gary R. Pasternack
-
Patent number: 5759837Abstract: Fatty acid synthase (FAS) is overexpressed in carcinomas with poor prognosis, but little FAS expression is identified in normal tissues Inhibition of fatty acid synthesis is selectively toxic to carcinoma cells, while normal cells with low FAS activity are resistant. This invention provides a method of treating cancer patients where fatty acid synthesis by cells of the patient's tumor is inhibited with resultant interruption of the disease process.Type: GrantFiled: January 24, 1994Date of Patent: June 2, 1998Assignee: John Hopkins UniversityInventors: Francis P. Kuhajda, Gary R. Pasternack
-
Patent number: 5756676Abstract: Three mammalian are disclosed which are useful in the diagnosis and prognosis of tumors of lymphoid and epithelial origin. The three proteins are immunologically related to each other. The level of expression of the proteins correlates with the malignant potential of lymphoid and epithelial tumors. In addition, in some cases the subcellular location of the proteins is indicative of malignant potential. Antibodies reactive with the proteins are disclosed as diagnostic tools, as are nucleic acid probes and primers for quantitating the messenger RNAs encoding the proteins. Methods for preparing and purifying the proteins are also taught.Type: GrantFiled: June 6, 1995Date of Patent: May 26, 1998Assignee: Johns Hopkins UniversityInventor: Gary R. Pasternack
-
Patent number: 5734022Abstract: Three mammalian nuclear proteins are disclosed which are useful in the diagnosis and prognosis of tumors of lymphoid and epithelial origin. The three proteins are immunologically related to each other. The level of expression of the proteins correlates with the malignant potential of lymphoid and epithelial tumors. In addition, in some cases the subcellular location of the proteins is indicative of malignant potential. Antibodies reactive with the proteins are disclosed as diagnostic tools, as are nucleic acid probes and primers for quantitating the messenger RNAs encoding the proteins. Methods for preparing and purifying the proteins are also taught.Type: GrantFiled: September 28, 1994Date of Patent: March 31, 1998Assignee: The Johns Hopkins UniversityInventor: Gary R. Pasternack
-
Patent number: 5726018Abstract: Three mammalian proteins are disclosed which are useful in the diagnosis and prognosis of tumors of lymphoid and epithelial origin. The three proteins are immunologically related to each other. The level of expression of the proteins correlates with the malignant potential of lymphoid and epithelial tumors. In addition, in some cases the subcellular location of the proteins is indicative of malignant potential. Antibodies reactive with the proteins are disclosed as diagnostic tools, as are nucleic acid probes and primers for quantitating the messenger RNAs encoding the proteins. Methods for preparing and purifying the proteins are also taught.Type: GrantFiled: June 6, 1995Date of Patent: March 10, 1998Assignee: Johns Hopkins UniversityInventor: Gary R. Pasternack
-
Patent number: 5665874Abstract: A method of determining the prognosis of a solid tumor is provided, in which a sample from a patient bearing a tumor is assayed for the presence of a protein which is immunologically cross-reactive with the hpr gene product, but not with haptoglobin 1 or haptoglobin 2. Also provided is a method for preparing antibodies specific for this diagnostic marker which correlates with early relapse and metastasis of breast and other cancers. The marker can be detected using immunological methods employing antibodies specific for Hpr protein and not cross-reactive with haptoglobins 1 or 2.Type: GrantFiled: June 5, 1995Date of Patent: September 9, 1997Assignee: John Hopkins UniversityInventors: Francis P. Kuhajda, Gary R. Pasternack